[{"id":"6d1b5764-e77a-48d0-bb8b-8c63cc77a81d","acronym":"LB1908-1001","url":"https://clinicaltrials.gov/study/NCT05539430","created_at":"2022-09-14T18:56:15.361Z","updated_at":"2024-07-02T16:35:15.456Z","phase":"Phase 1","brief_title":"Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma","source_id_and_acronym":"NCT05539430 - LB1908-1001","lead_sponsor":"Legend Biotech USA Inc","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN18.2 positive","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LB1908"],"overall_status":"Recruiting","enrollment":" Enrollment 56","initiation":"Initiation: 04/18/2023","start_date":" 04/18/2023","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-03-11"}]